KERALUX

KERALUX is the latest and most effective crosslinking technology for the treatment of keratoconus. The aim of the crosslinking method is to prevent disease progression and avoid de facto blindness. The cornea is mechanically strengthened by crosslinking the collagen fibres of the tissue in order to rectify the tissue weakness of the compromised cornea. To this end, the cornea is exposed to UV radiation with defined energy and wavelength. Prior to the procedure, a photoactive substance (riboflavin) is introduced into the cornea to facilitate the crosslinking of collagen by means of radiation.

Unfortunately, the conventional technology is burdened by a high treatment failure rate. KERALUX in turn avoids the treatment errors of the conventional technology caused by eye and head movements, by distance variation between the cornea and the radiation source, and by the curved and variable corneal geometry. Treatment with KERALUX is also quick and easy to perform in a private practice. KERALUX is a revolutionary and internationally patented technology which for the first time ever facilitates an optimised and defined energy transfer to the compromised cornea. For patients who are anxious, restless and unwilling to cooperate, KERALUX is the only crosslinking treatment option available. Unlike the large, impractical and expensive devices used by the conventional technology, KERALUX is a miniaturised disposable device for single use that can be applied easily, anywhere and anytime, allowing an optimised and automated treatment procedure thanks to its high-end microelectronics in monitored battery operation. KERALUX has already been approved as a medical device in the EU and has been successfully used in routine applications on humans for more than three years. Thanks to its highly innovative micro-technology and compact design, KERALUX is easily portable and can be used everywhere at any time. This makes it perfectly suitable for online sale, without the need of intermediaries. Despite its built-in cutting-edge technology, it is a relatively inexpensive device for single use, where physicians don't have to make high investments nor calculate payback periods. In contrast to the conventional standard procedure where the patient is exposed to radiation for about 30 minutes, the standard version of the KERALUX technology is designed for a radiation exposure of merely 10 minutes with the same energy output. KERALUX is not only the perfect product for private practices with low case figures; also clinical care centres with large patient numbers will medically and commercially benefit from KERALUX over the large, cumbersome and expensive conventional technology. KERALUX allows one physician and his team to treat several patients at a time, or even both eyes in one patient at the same time.

In Europe, between 1 out of 2000 inhabitants and 1 out of 1000 inhabitants suffers from keratoconus. In other regions of the world, this disorder is even more common. Especially in the Near East/Middle East, its frequency is in the single-digit range, and in endemic areas sometimes even in the double-digit range. As diagnostic methods improve, the relative incidence rate among the population in industrialised countries is increasing. The crosslinking technique is used to prevent disease progression and avoid de facto blindness. Treatment should therefore be initiated early, ideally at the onset of the disease, when visual acuity is still relatively good. The age when the first symptoms occur is usually between 10 and 30 years. The disease often deteriorates rapidly in the teenage years, so that patients are often already de facto blind before they reach the age of 20. Unfortunately, the stabilising effect of the crosslinking technique often lasts only 5 years and then has to be repeated.

Based on the epidemiological figures, the number of treatments requiring medical treatment can be estimated as follows: